Enzon Pharmaceuticals (OTCMKTS:ENZN) Stock Price Crosses Above Two Hundred Day Moving Average – What’s Next?

Shares of Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $5.56 and traded as high as $6.0750. Enzon Pharmaceuticals shares last traded at $5.85, with a volume of 3,485 shares.

Enzon Pharmaceuticals Stock Down 1.7%

The firm has a market cap of $4.33 million, a P/E ratio of -0.86 and a beta of -0.06. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.16 and a current ratio of 2.01. The firm’s fifty day moving average is $6.04 and its 200 day moving average is $5.56.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last announced its earnings results on Monday, May 4th. The biotechnology company reported ($0.84) EPS for the quarter. The company had revenue of $86.54 million for the quarter.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.